Holen Sie sich die Stockscreener-App
27.18
1.75%
-0.485
Handel nachbörslich:
27.18
Schlusskurs vom Vortag:
$27.66
Offen:
$27.47
24-Stunden-Volumen:
230.65K
Relative Volume:
0.41
Marktkapitalisierung:
$1.51B
Einnahmen:
$2.50M
Nettoeinkommen (Verlust:
$-131.12M
KGV:
-9.56
EPS:
-2.8431
Netto-Cashflow:
$-112.73M
1W Leistung:
-5.13%
1M Leistung:
-9.04%
6M Leistung:
-40.93%
1J Leistung:
+103.60%
1-Tages-Spanne:
$26.85
$27.61
1-Wochen-Bereich:
$26.42
$28.92
52-Wochen-Spanne:
$12.81
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
27.18 | 1.53B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-10 | Eingeleitet | Mizuho | Outperform |
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - marketbeat.com
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - marketbeat.com
Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa
Maze Therapeutics president sells $445,620 in company stock - Investing.com
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - marketbeat.com
Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - moomoo.com
HC Wainwright Has Positive Estimate for MAZE Q3 Earnings - marketbeat.com
Maze Therapeutics adds two directors to board By Investing.com - Investing.com Australia
Maze Therapeutics adds two directors to board - Investing.com
Maze Therapeutics Announces Appointments to Its Board of Directors - The Manila Times
Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors - Quiver Quantitative
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - kalkine.ca
Maze Therapeutics (NASDAQ:MAZE) Earns "Buy" Rating from BTIG Research - marketbeat.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - marketbeat.com
MAZE SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Maze Therapeutics (MAZE) reports $68.9M loss but ends Q2 with $494.9M in cash - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results - marketbeat.com
Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics Reports Q2 Net Loss Of $44.7 Million - Quiver Quantitative
Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses - TradingView
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
Press Release: Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - moomoo.com
Jason Coloma: The FTC Killed Our Sanofi Deal. Six Months Later, We Had a Better One. - finance.biggo.com
Maze Therapeutics (MAZE) Earnings Date and Reports 2026 - marketbeat.com
Maze Therapeutics (NASDAQ:MAZE) Trading Down 6.8%Should You Sell? - marketbeat.com
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics, Inc. (MAZE): Investor Outlook on a Biotech Stock with 119% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics, Inc. (MAZE) CEO Coloma sells 34,501 shares via trusts - Stock Titan
Form 144 Maze Therapeutics For: 3 August By Investing.com - Investing.com Canada
Maze Therapeutics, Inc. $MAZE Stake Reduced by Janus Henderson Group PLC - MarketBeat
MAZE PE Ratio & Valuation, Is MAZE Overvalued - Intellectia AI
Maze Therapeutics, Inc. (MAZE): Analyzing A 126% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $204,859.44 - Bitget
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MAZE (NASDAQ: MAZE) investor plans 22,500-share sale after option exercise - Stock Titan
TradingKey - TradingKey
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Spruce Street Capital LP Makes New $5.97 Million Investment in Maze Therapeutics, Inc. $MAZE - marketbeat.com
Maze Therapeutics, Inc. Revenue Breakdown – NASDAQ:MAZE - TradingView
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Cash Flow - TradingKey
Maze Therapeutics Inc (MAZE) Balance Sheet - TradingKey
MAZE|Maze Therapeutics Inc|Price:27.680| - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MAZE|Maze Therapeutics Inc|Price:28.685|Chg%:+1.005 - TradingKey
BABA: Alibaba Group Holding Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Maze Therapeutics (MAZE) Investor presentation Summary - Quartr
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):